JP2020503891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503891A5 JP2020503891A5 JP2019551736A JP2019551736A JP2020503891A5 JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5 JP 2019551736 A JP2019551736 A JP 2019551736A JP 2019551736 A JP2019551736 A JP 2019551736A JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cell
- car
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017202A JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432302P | 2016-12-09 | 2016-12-09 | |
| US62/432,302 | 2016-12-09 | ||
| PCT/EP2017/082292 WO2018104562A1 (en) | 2016-12-09 | 2017-12-11 | Engineered natural killer cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Division JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503891A JP2020503891A (ja) | 2020-02-06 |
| JP2020503891A5 true JP2020503891A5 (https=) | 2021-01-21 |
| JP7228900B2 JP7228900B2 (ja) | 2023-02-27 |
Family
ID=60937693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551736A Active JP7228900B2 (ja) | 2016-12-09 | 2017-12-11 | 操作されたナチュラルキラー細胞およびその使用 |
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10799536B2 (https=) |
| EP (4) | EP3895712B1 (https=) |
| JP (2) | JP7228900B2 (https=) |
| KR (1) | KR20190114966A (https=) |
| CN (2) | CN110248669B (https=) |
| AU (1) | AU2017371517B2 (https=) |
| BR (1) | BR112019011450A2 (https=) |
| CA (1) | CA3045386A1 (https=) |
| DK (2) | DK3454871T3 (https=) |
| ES (3) | ES2746856T3 (https=) |
| MX (1) | MX2019006598A (https=) |
| WO (1) | WO2018104562A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| JP7158104B2 (ja) * | 2016-07-15 | 2022-10-21 | ビラクタ セラピューティクス，インク． | Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤 |
| WO2018104562A1 (en) * | 2016-12-09 | 2018-06-14 | Onkimmune Limited | Engineered natural killer cells and uses thereof |
| US20210228630A1 (en) * | 2018-05-16 | 2021-07-29 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
| JP7241161B2 (ja) | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| US20210361706A1 (en) * | 2018-08-29 | 2021-11-25 | Academia Sinica | Combination of natural killer cells with cyclophosphamide compounds for the treatment of cancer |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020189942A1 (ko) * | 2019-03-15 | 2020-09-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| KR102292657B1 (ko) * | 2019-03-15 | 2021-08-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| CN109970869A (zh) * | 2019-04-12 | 2019-07-05 | 南京卡提医学科技有限公司 | 一种靶向人trail死亡受体的嵌合受体配体及其应用 |
| WO2020220027A1 (en) * | 2019-04-25 | 2020-10-29 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| KR20220093337A (ko) * | 2019-10-31 | 2022-07-05 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Cd38 녹아웃 일차 및 확장된 인간 nk 세포의 생성 |
| TW202146644A (zh) * | 2020-01-16 | 2021-12-16 | 育世博生物科技股份有限公司 | 一種新穎的ｃｄ１６陽性自然殺手細胞及一種培養ｃｄ１６陽性自然殺手細胞的方法 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| WO2021209625A1 (en) * | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
| US20230293670A1 (en) * | 2020-08-27 | 2023-09-21 | Cellid Co., Ltd. | Novel coronavirus recombinant spike protein, polynucleotide encoding same, vector comprising polynucleotide, and vaccine for preventing or treating coronavirus infection, comprising vector |
| EP4204546A1 (en) | 2020-08-31 | 2023-07-05 | City of Hope | Novel cell lines, methods of producing natural killer cells and uses thereof |
| CN114426583B (zh) * | 2020-10-29 | 2023-10-10 | 中国科学技术大学 | 用于急性髓系白血病的细胞疗法的嵌合抗原受体 |
| KR20220091426A (ko) | 2020-12-23 | 2022-06-30 | 주식회사 휴먼셀바이오 | 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물 |
| JP2024522756A (ja) | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| US20240316102A1 (en) | 2021-07-01 | 2024-09-26 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| EP4377464A4 (en) * | 2021-07-29 | 2025-07-09 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | SYNTHETIC NUCLEIC ACID ELEMENTS TO IMPROVE CAR-T CELL EFFICACY |
| EP4402155A4 (en) * | 2021-09-18 | 2025-12-24 | Sunnybay Biotech Inc | ANTI-HERV-K ANTIBODIES, CELL, VACCINE AND DRUG THERAPEUTIC AGENTS |
| CA3239740A1 (en) * | 2021-12-03 | 2023-06-08 | Tim C. LEUTKENS | High selective cd229 antigen binding domains and methods of use |
| JP2025525439A (ja) | 2022-06-30 | 2025-08-05 | インダプタ セラピューティクス インコーポレイテッド | 操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法 |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| JP2025536042A (ja) | 2022-11-10 | 2025-10-30 | オーエヌケイ セラピューティクス リミテッド | 免疫調節薬を用いた併用療法 |
| KR20260010740A (ko) * | 2023-05-12 | 2026-01-21 | 주식회사 엔케이젠바이오텍코리아 | 확장된 자연 살해 세포를 이용한 알츠하이머병 치료 방법 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025073908A1 (en) | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| WO2025146467A1 (en) | 2024-01-04 | 2025-07-10 | Onk Therapeutics Limited | Targeted il-15 construct delivery |
| KR20250118299A (ko) | 2024-01-29 | 2025-08-06 | 인하대학교 산학협력단 | 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법 |
| WO2025184169A1 (en) * | 2024-02-26 | 2025-09-04 | The Regents Of The University Of California | Oleate-mediated enhancement of human natural killer cell function |
| WO2025239292A1 (ja) * | 2024-05-15 | 2025-11-20 | 株式会社Cured | 改変ナチュラルキラー細胞株 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004213432A1 (en) * | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Novel therapeutic targets in cancer |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| WO2008037257A2 (en) | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| CA2667067A1 (en) | 2006-10-19 | 2008-04-24 | Merck & Co., Inc. | Antibody antagonists of interleukin-13 receptor .alpha.1 |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| SMT202000031T1 (it) | 2010-06-09 | 2020-03-13 | Genmab As | Anticorpi contro cd38 umano |
| ES2671004T3 (es) | 2013-03-07 | 2018-06-04 | Baylor College Of Medicine | Dirección a CD138 en cáncer |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US10934346B2 (en) * | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| MX387665B (es) | 2014-12-24 | 2025-03-18 | Aadigen Llc | Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos. |
| JP6797803B2 (ja) | 2014-12-31 | 2020-12-09 | セルジーン コーポレイション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP4286511A3 (en) | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| JP6974681B2 (ja) | 2015-07-29 | 2021-12-01 | オーエヌケー セラピューティクス リミテッド | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2018104562A1 (en) | 2016-12-09 | 2018-06-14 | Onkimmune Limited | Engineered natural killer cells and uses thereof |
| US20180344768A1 (en) | 2016-12-09 | 2018-12-06 | Onkimmune Limited | Nk cell-based therapy |
| US20190321402A1 (en) | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with anitbodies in cancer therapy |
-
2017
- 2017-12-11 WO PCT/EP2017/082292 patent/WO2018104562A1/en not_active Ceased
- 2017-12-11 EP EP21160170.3A patent/EP3895712B1/en active Active
- 2017-12-11 JP JP2019551736A patent/JP7228900B2/ja active Active
- 2017-12-11 EP EP22179362.3A patent/EP4104841A1/en active Pending
- 2017-12-11 KR KR1020197019363A patent/KR20190114966A/ko not_active Ceased
- 2017-12-11 AU AU2017371517A patent/AU2017371517B2/en active Active
- 2017-12-11 BR BR112019011450-5A patent/BR112019011450A2/pt not_active IP Right Cessation
- 2017-12-11 EP EP17825774.7A patent/EP3454871B1/en active Active
- 2017-12-11 DK DK17825774.7T patent/DK3454871T3/da active
- 2017-12-11 ES ES17825774T patent/ES2746856T3/es active Active
- 2017-12-11 ES ES19176141T patent/ES2875005T3/es active Active
- 2017-12-11 CN CN201780085686.0A patent/CN110248669B/zh active Active
- 2017-12-11 CA CA3045386A patent/CA3045386A1/en active Pending
- 2017-12-11 MX MX2019006598A patent/MX2019006598A/es unknown
- 2017-12-11 DK DK19176141.0T patent/DK3581190T3/da active
- 2017-12-11 ES ES21160170T patent/ES2926397T3/es active Active
- 2017-12-11 CN CN202311063691.5A patent/CN117305250A/zh active Pending
- 2017-12-11 US US15/837,576 patent/US10799536B2/en active Active
- 2017-12-11 EP EP19176141.0A patent/EP3581190B1/en active Active
-
2020
- 2020-08-31 US US17/008,506 patent/US12534536B2/en active Active
-
2023
- 2023-02-07 JP JP2023017202A patent/JP2023052980A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503891A5 (https=) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| JP2016520074A5 (https=) | ||
| PH12018501778A1 (en) | Antibodies to tigit | |
| MX2022007791A (es) | Partes de unión a claudin18.2 y usos de estas. | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| JP2012254092A5 (https=) | ||
| JP2020526214A5 (https=) | ||
| JP2017518258A5 (https=) | ||
| JP2016502515A5 (https=) | ||
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| JP2015535691A5 (https=) | ||
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| JP2017513478A5 (https=) | ||
| JP2014039548A5 (https=) | ||
| JP2015131795A5 (https=) | ||
| WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
| JP2018524326A5 (https=) | ||
| JP2017537972A5 (https=) | ||
| JP2018509163A5 (https=) | ||
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. |